Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oncosec Medical (ONCS)

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
OncoSec Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Application with Claims Covering Cytokine-Based Intratumoral Immunotherapies

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has...

ONCS : 1.94 (-3.00%)
OncoSec Issues Letter to Shareholders

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today published a Letter to Shareholders from President and Chief Executive Officer,...

ONCS : 1.94 (-3.00%)
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that it has entered into a collaboration with Dana-Farber Cancer...

ONCS : 1.94 (-3.00%)
Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

PRTY : 4.80 (+0.42%)
PULM : 0.86 (+2.54%)
HPQ : 18.91 (-1.56%)
ONCS : 1.94 (-3.00%)
ABBV : 66.41 (-0.23%)
Bet on 5 Top Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

PRTY : 4.80 (+0.42%)
PULM : 0.86 (+2.54%)
HPQ : 18.91 (-1.56%)
ONCS : 1.94 (-3.00%)
ABBV : 66.41 (-0.23%)
OncoSec Announces Collaboration For TAVO(TM) In Australia With Emerge Health

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, and Emerge Health Pty (Emerge), the leading Australian company providing full registration,...

ONCS : 1.94 (-3.00%)
OncoSec Medical (ONCS) Looks Good: Stock Adds 6.6% in Session

OncoSec Medical (ONCS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

ANIK : 55.68 (-3.11%)
ONCS : 1.94 (-3.00%)
OncoSec Medical Incorporated Prices $11,000,000 Public Offering

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, today announced the pricing of an underwritten public...

ONCS : 1.94 (-3.00%)
OncoSec to Present at ThinkEquity Conference 2019

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer...

ONCS : 1.94 (-3.00%)
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to it's Board of Directors

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the appointment of Margaret R. Dalesandro, Ph.D., to the Company's Board...

ONCS : 1.94 (-3.00%)
OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO(TM), Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced a triple combination clinical trial of OncoSec's TAVO(TM), epacadostat, and...

ONCS : 1.94 (-3.00%)
OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO(TM) in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, and Duke University School of Medicine, today announced that they have entered into a collaborative...

ONCS : 1.94 (-3.00%)
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the development of a new, propriety technology to potentially treat pancreatic,...

ONCS : 1.94 (-3.00%)
OncoSec to Present at H.C. Wainwright Global Life Sciences Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Dan O'Connor, President, Director & Chief Executive Officer, will present...

ONCS : 1.94 (-3.00%)
OncoSec's KOL Symposium Sheds New Light on the Importance of IL-12 Use Via OncoSec's Technology and Provides Updates on TAVO's Clinical Progress

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, provided an update on recent pipeline and regulatory progress during a Key Opinion Leader...

ONCS : 1.94 (-3.00%)
Biotech Firms Strive to Combat the Growing Burden of Diseases With Innovative Technologies

NEW YORK, April 4, 2019 The global burden of diseases continues to grow each year, despite various ongoing medical advancements. In 2017, the Institute for Health Metrics and Evaluation (IHME) said in...

SRNE : 2.28 (-0.87%)
ARQL : 9.23 (+3.36%)
ONCS : 1.94 (-3.00%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
SNSS : 0.83 (-1.28%)
OncoSec Presents Promising Preclinical Data with New Product Candidate and Improved Electroporation Generator at AACR Annual Meeting

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing novel cancer immunotherapies, today presented pre-clinical data highlighting its novel anti-tumor product candidate, SPARK(TM),...

ONCS : 1.94 (-3.00%)
OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO(TM) in Refractory Metastatic Melanoma

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing novel cancer immunotherapies, announced today that it has received Advanced Therapy Medicinal Product (ATMP) classification for...

ONCS : 1.94 (-3.00%)
OncoSec To Host Key Opinion Leader Symposium On April 5, 2019

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that the Company will host a Key Opinion Leader (KOL) Symposium focused...

ONCS : 1.94 (-3.00%)
OncoSec to Present at the 31st Annual ROTH Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that management will present in the 31st Annual ROTH Conference taking place...

ONCS : 1.94 (-3.00%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
AIZ -1.07 , WELL -0.87 , SBAC -0.79 , CCI -0.35 , SO -0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar